Yamo Pharmaceuticals LLC
2 clinical trials · Sponsor
◉ Watch Yamo Pharmaceuticals LLC
| Record | Firm | Date |
|---|---|---|
| A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder (NCT05067582) | Yamo Pharmaceuticals LLC | 2022-01-25 |
Track Yamo Pharmaceuticals LLC automatically
Every clearance here is in the API, with alerts when new ones post.